Pembrolizumab In Central Nervous System Metastases
Phase 2
Active, not recruiting
NCT02886585
| Condition | Brain Metastases |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Massachusetts General Hospital |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 101 participants |
|---|
| Interventions | Pembrolizumab, MRI, PET/CT, Stereotactic Radiosurgery |
|---|
| Start date | Oct, 2016 |
|---|
| Completion date | Jun, 2027 |
|---|
| Results posted | Jun 26, 2026 |
|---|
Summary
This research study is studying Pembrolizumab as a possible treatment for this diagnosis for metastases in the central nervous system (brain and spinal cord).
Intracranial Benefit Rate (Cohorts A and B)
44 months · percentage of patients
| Previously Untreated Brain Metastases-Cohort A | 33.3 percentage of patients |
|---|
| Progressive Brain Metastases-Cohort B | 43.8 percentage of patients |
|---|
Overall Survival at Three Months (Cohort C)
3 Months · proportion of patients
| Neoplastic Meningitis-Cohort C | 0.60 proportion of patients |
|---|
Extracranial Overall Response Rate (Cohort D)
Data collection is ongoing for this objective. The longest time a single patient has been followed for this measure is 6 years.
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.